Heme binding in the NEAT domains of IsdA and IsdC of Staphylococcus aureus

Journal of Inorganic Biochemistry
Mark PluymMartin J Stillman

Abstract

Absorption, magnetic circular dichroism (MCD), and electrospray mass spectral (ESI-MS) data are reported for the heme binding NEAr iron Transporter (NEAT) domains of IsdA and IsdC, two proteins involved in heme scavenging by Staphylococcus aureus. The mass spectrometry data show that the NEAT domains are globular in structure and efficiently bind a single heme molecule. In this work, the IsdA NEAT domain is referred to as NEAT-A, the IsdC NEAT domain is referred to as NEAT-C, heme-free NEAT-C is NEAT-A and NEAT-C are inaccessible to small anionic ligands. Reduction of the high-spin Fe(III) heme iron to 5-coordinate high-spin Fe(II) in NEAT-A results in coordination by histidine and opens access, allowing for CO axial ligation, yielding 6-coordinate low-spin Fe(II) heme. In contrast, reduction of the high-spin Fe(III) heme iron to 5-coordinate high-spin Fe(II) in NEAT-C results in loss of the heme from the binding site of the protein due to the absence of a proximal histidine. The absorption and MCD data for NEAT-A closely match those previously reported for the whole IsdA protein, providing evidence that heme binding is primarily a property of the NEAT domain.

References

Apr 25, 1979·Biochimica Et Biophysica Acta·W R Browett, M J Stillman
Feb 1, 1988·Journal of Bacteriology·J M LiS D Cosloy
Feb 15, 1987·Analytical Biochemistry·E A Berry, B L Trumpower
Jun 1, 1984·Biophysical Chemistry·W R Browett, M J Stillman
Feb 8, 2003·Science·Sarkis K MazmanianOlaf Schneewind
Jun 10, 2003·Journal of Mass Spectrometry : JMS·Vincenzo CunsoloM Ph Verbeet
Jul 9, 2004·Biochemical and Biophysical Research Communications·John MackMartin J Stillman
Oct 18, 2006·Biochemistry·Christie L VermeirenMartin J Stillman
Jan 19, 2007·Molecular Microbiology·Jason C GriggMichael E P Murphy

❮ Previous
Next ❯

Citations

Aug 26, 2014·PloS One·Erin S HonsaSarah K Highlander
Jan 25, 2011·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Erin Sarah Honsa, Anthony William Maresso
Aug 5, 2008·The Journal of Biological Chemistry·Naomi MuryoiMartin J Stillman
Aug 30, 2008·PLoS Pathogens·Anthony W MaressoOlaf Schneewind
May 4, 2010·Journal of Bacteriology·Yael TarlovskyAnthony W Maresso
Jun 26, 2012·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Michael T Tiedemann, Martin J Stillman
Apr 7, 2009·Biochemical and Biophysical Research Communications·Halina WójtowiczTeresa Olczak
Jan 27, 2009·Biochemical and Biophysical Research Communications·Ryota AbeKouhei Tsumoto
Oct 20, 2015·Biochemistry·Elizabeth B DraganovaDabney W Dixon
May 8, 2013·Protein Science : a Publication of the Protein Society·Nhuan T VuKouhei Tsumoto
May 2, 2014·Current Opinion in Chemical Biology·Heidi ContrerasCelia W Goulding
Sep 7, 2011·Journal of Molecular Biology·Jason C GriggMichael E P Murphy
Jul 12, 2017·Protein Science : a Publication of the Protein Society·Takahide YamaguchiTakamitsu Kohzuma
Apr 25, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Guizhen WangHongsu Wang
Oct 12, 2018·The Journal of Biological Chemistry·Ramsay MacdonaldRobert T Clubb

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.